tetano
Editor, Senior Moderator
J Infect Dis
. 2020 Aug 15;jiaa508.
doi: 10.1093/infdis/jiaa508. Online ahead of print.
Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay
Edward P Gniffke[SUP] 1 [/SUP], Whitney E Harrington[SUP] 2 3 [/SUP], Nicholas Dambrauskas[SUP] 2 [/SUP], Yonghou Jiang[SUP] 2 [/SUP], Olesya Trakhimets[SUP] 2 [/SUP], Vladimir Vigdorovich[SUP] 2 [/SUP], Lisa Frenkel[SUP] 2 3 [/SUP], D Noah Sather[SUP] 2 3 [/SUP], Stephen E P Smith[SUP] 1 3 4 [/SUP]
Affiliations
Abstract
We present a microsphere-based flow cytometry assay that quantifies the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2). Plasma from 22 subjects who recovered from mild Coronavirus disease 2019 (COVID-19) and expressed anti-spike-trimer IgGs inhibited ACE2-spike binding to a greater degree than controls. The degree of inhibition correlated with anti-spike IgG levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever during illness. This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID-19 patients or vaccine recipients in a cell-free assay system.
Keywords: ACE2; COVID-19; SARS-COV-2; Spike; binding inhibition; neutralization; serology.
. 2020 Aug 15;jiaa508.
doi: 10.1093/infdis/jiaa508. Online ahead of print.
Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay
Edward P Gniffke[SUP] 1 [/SUP], Whitney E Harrington[SUP] 2 3 [/SUP], Nicholas Dambrauskas[SUP] 2 [/SUP], Yonghou Jiang[SUP] 2 [/SUP], Olesya Trakhimets[SUP] 2 [/SUP], Vladimir Vigdorovich[SUP] 2 [/SUP], Lisa Frenkel[SUP] 2 3 [/SUP], D Noah Sather[SUP] 2 3 [/SUP], Stephen E P Smith[SUP] 1 3 4 [/SUP]
Affiliations
- PMID: 32798222
- DOI: 10.1093/infdis/jiaa508
Abstract
We present a microsphere-based flow cytometry assay that quantifies the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2). Plasma from 22 subjects who recovered from mild Coronavirus disease 2019 (COVID-19) and expressed anti-spike-trimer IgGs inhibited ACE2-spike binding to a greater degree than controls. The degree of inhibition correlated with anti-spike IgG levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever during illness. This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID-19 patients or vaccine recipients in a cell-free assay system.
Keywords: ACE2; COVID-19; SARS-COV-2; Spike; binding inhibition; neutralization; serology.